Image
Loading
Multigene panel testing in gynaecological malignancies: A study in a cohort of over 1000 patients

Alexandros Mpokas, Eleni Timotheadou, Ioannis Boukovinas, Mustafa Özdogan, Diana Chetroiu, Polixenia Iorga, Ioannis Syrios, Eleni Isidora Perdikouri, Dimitrios Ziogas, Foteinos Ioannis Dimitrakopoulos, Charisios Karanikiotis, Maria Paraskeva, Christina Ntogka, Kevisa Potska, Athanasios Papathanasiou, Angeliki Meintani, Dimitra Bouzarelou, Georgios N Tsaousis, Eirini Papadopoulou, George Nasioulas

Distribution of molecular subtypes in endometrial cancer following the updated 2025 ESGO-ESTRO-ESP guidelines: A prospective cohort study.

Dimitrios Tsolakidis, Dimitrios Zouzoulas, Katerina Vlataki, Mara Vlachou, Artemis Mihala,
Konstantinos Eleftheriadis, Fani Stamkou, Grigorios Grimbizis, Andreas Kavallaris, Christos
Kotanidis, Panagiotis Giannakas, Anca-Maria Manta, Petre Bratila, Dimitrios Minotakis, Stella
Maxouri, Katerina Tsantikidi, Vasiliki Metaxa-Mariatou, Eirini Papadopoulou, Georgios Nasioulas

Integrative sWGS: A New Paradigm for HRD Detection in Ovarian Cancer

Dan Corneliu Jinga, Georgiana Duta-Cornescu, Danut Cimponeriu, Eirini Papadopoulou, Angeliki Meintani, George Tsaousis, Amalia Chirnogea, Irina Bucatariu, Polixenia-Georgeta Iorga, Diana Chetroiu, Sorin-Cornel Hosu, Amalia Hogea-Zah, Mircea-Dragos Median, Bogdan Diana, Dana-Lucia Stănculeanu, Raluca Mihaila, Dana-Sonia Nagy, Pompilia-Elena Motatu, Turcanu Eugeniu, Elena-Octaviana Cristea, Ion-Cristian Iaciu, Paul Kubelac and Andreea Truican.

Evaluation of the 1021-HRD assay compared to established HRD testing platforms in ovarian cancer

Eirini Papadopoulou, Elena Fountzilas, Vasiliki Metaxa-Mariatou, Aikaterini Tsantikidi, Georgios Tsaousis, Angeliki Meintani, Chrysiida Florou-Chatzigiannidou, Stella Maxouri, Konstantinos Papazisis, Theofanis Floros, Christos Papadimitriou, Eleni Timotheadou, Kyriaki Papadopoulou, Athanasios Papathanasiou, Dimitrios Grigoriadis, Xiaorui Fu, Xunmei Zheng, Yun Xing, Xinhua Du, Andreea Truican, George Nasioulas

Integrated NGS-Based Tissue and Plasma Profiling to Advance Precision Oncology in Breast Cancer

D. Mavroudis, D. Jinga, E. Razis, S. Giassas, N. Touroutoglou, C. Bilir, M. Ozdogan, I. Ökten, S. Karageorgopoulou, E. Galani, G. ElHachem, D. Tzanninis, T. Floros, G. Lazaridis, P. Vlachostergios, I. Hacibekiroglu, E. Maragkouli, I. Gioulbasanis, A. Tsantikidi, S. Maxouri, C. Florou-Chatzigiannidou, V. Metaxa-Mariatou, E. Papadopoulou, D. Grigoriadis, A. Papathanasiou, G. Nasioulas

Association of Oncotype DX Recurrence Score with Germline Mutations in Cancer Susceptibility Genes Including BRCA1/2 in HR+/HER2- Early Breast Cancer

Venizelos V., Papazisis K., Markopoulos C., Xepapadakis G., Iosifidou R., Kapetsis G., Giannoulakis S., Tsoulos N., Meintani A., Bouzarelou D., Tsaousis G., Grosomanidis D., Bredakis N., Zagouri F., Christodoulou C., Anastasakou K., Paraskeva M., Mavroudis D., Michalopoulos N., Tryfonopoulos D., Papadopoulos S., Adamidis A., Dimas D., Angelidou E., Papadopoulou E., Nasioulas G.

High-prevalence of NF1 pathogenic variants in cancer patients without classic features of Neurofibromatosis type 1A

A. Koutras, K. Papazisis, I. Boukovinas, R. Iosifidou, I. Intzidis, K. Potska, C. Dogka, A. Katseli, D. Paranou, A. Karavaggeli, A. Meintani, D. Bouzarelou, D. Lachanas, G. Rigas, M. Kanara, M. Müslümanoglu, I. Bobolaki, E. Biziota, E. Papadopoulou, G. Nasioulas

High-Risk cancer susceptibility genes mutation carriers’ compliance with surgical risk reduction for breast and ovarian cancer

K. Papazisis, M. Paraskeva, S. Giassas, M. Skondra, R. Iosifidou, C. Tolis, G. Kesisis, E. Zairi, V. Venizelos, C. Markopoulos, I. Natsiopoulos, E. Bleka, I. Xanthakis, A. Ananiadis, D. Matthaios, D. Stefanou, A. Adamidis, A. Meintani, G. Kapetsis, D. Bouzarelou, E. Papadopoulou, G. Nasioulas

Performance of a 52-gene NGS panel combined with shallow WGS for accurate HRD analysis.

Paul Kubelac Milan, Iulian Hotinceanu, Andreea Truican, Mioara-Maria Caldaraș, Vlad Alexandru Manolescu, Iulia Monica Groza, Cristian-Ervin Gal, Dana Lucia Stanculeanu,
Aurelia Alexandru, Polixenia Iorga, Dragos Mircea Median, Loredana Tuinea, Bogdan Gafton, Simona Volovat, Rareș Tiberiu Moldovan, Norina Macra, Daniela Nagy,
Florinel Pop, Eirini Papadopoulou, George Nasioulas

Analytical validation of a 1021-gene NGS panel for comprehensive tumor profiling in FFPE and liquid biopsy samples

Dimitrios Matthaios, Angeliki Meintani, Eirini Papadopoulou, Vasiliki Metaxa-Mariatou, Chrysiida Chatzigiannidou-Florou, Mustafa Ozdogan, ¨Onder Kirca,
Nikolaus Mitsimponas, Georgios Lypas, Jim Janinis, Vassilios Ramfidis, Dimitrios C. Ziogas, Maria Theochari, Foteinos-Ioannis Dimitrakopoulos, Nikolaos Touroutoglou,
George Papatsibas, Ioannis Boukovinas, Panagoula Kollia, Andreas Agathangelidis, George Nasioulas

Multigene NGS assay for biomarker identification in 621 colorectal cancer cases.

Athanasios Kotsakis, Eleni Thanou, Maria Vlachou, Aikaterini Tsantikidi, Artemis Mihala, Stefania Gkoura, Georgios Karkaletsos, Flora Stavridi, Kyriakos Amarantidis,
Stefanos Dimoudis, Ioannis Samaras, Konstantinos Botsolis, Achilleas Adamidis, Charisios Karanikiotis, Georgios Zarkavelis, Andreas Evangelos Makrantonakis,
Cagatay Arslan, Mukremin Uysal, Eirini Papadopoulou, George Nasioulas

Evaluation of a 1021-gene NGS panel for HRD detection in clinical samples.

Elena Fountzilas, Eirini Papadopoulou, Vasiliki Metaxa-Mariatou, Stella Maxouri, Aikaterini Tsantikidi, Chrysiida Chatzigiannidou-Florou, Konstantinos Papazisis, Christos
A. Papadimitriou, Theofanis Floros, Michael Liontos, Alexandros Bokas, Eleni Timotheadou, Anastasios L. Boutis, Prokopios Dimopoulos, Xiaorui Fu, Yun Xing,
Xunmei Zheng, Xinhua Du, George Nasioulas

Detection of ESR1 and PIK3CA actionable mutations in breast cancer using liquid biopsy: A step toward precision medicine.

Athina Christopoulou, Maria Vlachou, Sofia Karageorgopoulou, Flora Zagouri, Eleni Galani, Aikaterini Tsantikidi, Maria Aslani Gkotzamanidou, Angelos Koutras,
Alexandros Tzovaras, Alexandros Bokas, Eirini Biziota, Vicky Vasiliki Rizouli, Dimitrios Dionysopoulos, Zafeiris Zafeiriou, Eleni Zairi, Athanasios Papathanasiou,
Dimitrios Grigoriadis, Maria Paraskeva, Eirini Papadopoulou, George Nasioulas

Molecular profiling using NGS in lung cancer patients: Revolutionizing targeted therapy and personalized treatment.

Sofia Agelaki, Giannis Socrates Mountzios, Konstantinos Samitas, Maria Vlachou, Eleni Thanou, Artemis Mihala, Aikaterini Tsantikidi, Eleftherios Zervas,
Anna Koumarianou, Konstantinos Laschos, Danai Daliani, Triantafyllia Koukaki, Eleni Sogka, Sofia Baka, Georgios Lazaridis, Anna Andreadou, Ilker Nihat Okten, Tulay Kus,
Eirini Papadopoulou, George Nasioulas

Exploring the Genomic Identity of Metastatic Melanoma Beyond BRAF Status: Insights from Next-Generation Sequencing for Comprehensive Profiling in Metastatic Melanoma Patients

D. Ziogas, I. Papadopoulou, A. Anastasopoulou,
C. Theocharopoulos, D. Stefanou, G. Lyrarakis,
I. Boukovinas, M. Theochari, D. Bafaloukos, T. Floros,
V. Metaxa-Mariatou, A. Tsantikidi, A. Meintani,
G.N. Tsaousis, G. Nasioulas, H. Gogas

Li-Fraumeni:”Genetic testing of Breast/ovarian cancer patients unmask familial pathogenic germline variants in TP53 gene. Clinical implications and family counselling.

A. Zavos, I. Natsiopoulos, K. Papazisis, S. Giassas, A. Tsiftsoglou, D. Bouzarelou, A. Meintani, A. Katseli, V. Potska, C. Dogka, G. Tsaousis, R. Iosifidou, E. Lalla, I. Askoxylakis, E. Zairi, A. Kotsakis, D. Tryfonopoulos, A. Christopoulou, A. Ntokou, K. Mandrekas, D. Bafaloukos, A. Sfika, R. Zakopoulou, P. Markellou, E. Papadopoulou, G. Nasioulas

The Benefit sof comprehensive NGS Panels using Liquid Biopsy in Breast Cancer

S. Karageorgopoulou, A. Koumarianou, S. Giassas, P. Oikonomopoulou, E. Galani, A. Kotsori, K. Papazisis, N. Touroutoglou, X. Karanikiotis, M. Paraskeva, A. Mpokas, A. Cristopoulou, E. Tripodaki, N. Alevizopoulos, K. Rapti, A. Andreadou, M. Theochari, T. Kus, I. Hacibekiroglu, Ç. Arslan, A. Tsantikidi, V. Metaxa-Mariatou, E. Thanou, C. Florou-Chatzigiannidou, M. Vlachou, V. Karamani, S. Maxouri, E. Papadopoulou, G. Nasioulas

Exploring the clinical utility of Oncotype DX in ER+/HER2-, N0 and N1 breast cancer patients: Insights from a Romanian cohort

A. Blidaru, D. Zob, M. Schenker, A. Onisim, C. Bodale, R. Curcă, Ș. Negru, C. Oprean, P. Curescu, B. Gafton, S. Volovăț, R. Mihăilă, G. Filip, D. Median, M. Dediu, D. Chetroiu, I. Pantelimon, C. Costovici, C. G. Viișoreanu, V. Titirez, D. Mateescu, C. Gal, G. Vremeș, D. L. Stănculeanu, N. Tsoulos, G. Kapetsis, S. Giannoulakis, A. Sireș, A. Chirnogea, A.-I. Maxim, P. Iorga, D.-C. Jinga, C. Nițipir

Genomic risk assessment with Oncotype DX in young women (age≤ 40 years old) with early-stage ER+/HER2-/N0 breast cancer

R. Iosifidou, G. Xepapadakis, V. Venizelos, C. Markopoulos, K. Papazisis, N. Tsoulos, G. Kapetsis, S. Giannoulakis, M. Paraskeva, M. Kaparelou, G. Lainakis, A. Fotarelli, F. Pavlidou, E. Fountzilas, E. Saloustros, S. Karageorgopoulou, S. Triantafillidou, S. Intzes, F. Koinis

The prognostic role of Ki-67 in relation to Oncotype DX Recurrence Score

C. Markopoulos, A. Koumarianou, V. Venizelos, R. Iosifidou, K. Papazisis, N. Tsoulos, G. Kapetsis, S. Giannoulakis, S. Giassas, I. Foivos, V. Gaki, A. Pazaiti, K. Anastasakou, E. Timotheadou, K. Koutsoukos, T. Kontoulis, E. Kostouros, I. Gkioulbasanis, D. Nasikas, D. Matheos

Examining the Correlation and Concordance Between Ki-67 Expression and Oncotype DX Recurrence Score: Findings from a Multicenter Study in Turkey

C. Uras, N. Tsoulos, S. Giannoulakis, G. Kapetsis, M. Cerkez Ergoren, P. Olgun, O. Diker, H. Karanlik, C. Bilir, C. Arslan, A. Igci, B. Karabulut, G. Gorumlu, O. Butun, N. Gulum, O. Kirca, M. Ozdogan

PR status cannot predict Oncotype DX Recurrence Score®: a study in a Greek cohort of N0M0/ER+/PR-/HER2- breast cancer patients tested with Oncotype DX

Venizelos V., Iosifidou R., Markopoulos C., Xepapadakis G., Tsoulos N., Giannoulakis S., Kapetsis G., Psyrri A., Saridaki Z., Natsiopoulos I., Nikolaidi A., Savvidou A., Mpoutis A., Mpoukovinas I., Kotsakis A., Christopoulou A., Saloustros E., Mavroudis D., Aggelaki S., Assi A., Tzanninis D., Grosomanidis D., Fountzilas E., Lala E., Ignatiadou E., Skondra M., Zagouri F., Koumarianou A., Kosmidis P., Douvetzemis S., Papazisis K., Anastasakou K., Pavlidou F., Kampletsas E., Poulakaki F., Simpilidis G., Triantafillidou S., Stathoulopoulou M.

The prognostic and predictive value of Oncotype DX® in ER+/HER2-/pT2N0, cM0 Breast Cancer Patients

Natsiopoulos I., Iosifidou R., Markopoulos C., Xepapadakis G., Tsoulos N., Giannoulakis S., Kapetsis G., Psyrri A., Saridaki Z., Venizelos V., Nikolaidi A., Savvidou A., Mpoutis A., Mpoukovinas I., Kotsakis A., Christopoulou A., Saloustros E., Mavroudis D., Aggelaki S., Assi A., Tzanninis D., Grosomanidis D., Fountzilas E., Lala E., Ignatiadou E., Skondra M., Zagouri F., Koumarianou A., Kosmidis P., Douvetzemis S., Papazisis K., Anastasakou K., Pavlidou F., Kampletsas E., Poulakaki F., Simpilidis G., Triantafillidou S., Stathoulopoulou M.

Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice

Eirini Papadopoulou, PhD1 ; George Rigas, MD2; Elena Fountzilas, MD, PhD3 ; Anastasios Boutis, MD, PhD4; Stylianos Giassas, MD5;
Nikolaos Mitsimponas, MD, MSc6; Danai Daliani, MD7 ; Dimitrios C Ziogas, MD8; Michalis Liontos, MD, PhD9 ; Vasileios Ramfidis, MD, MSc10; Charalampos Christophilakis, MD11; Dimitris Matthaios, MD, PhD12; Theofanis Floros, MD13; Chrysiida Florou-Chatzigiannidou, MSc1; Konstantinos Agiannitopoulos, MSc, PhD1; Angeliki Meintani, MSc1; Aikaterini Tsantikidi, MSc1; Anastasia Katseli, PhD1 ; Kevisa Potska, MSc1; Georgios Tsaousis, MSc, PhD1 ; Vasiliki Metaxa-Mariatou, MSc1; and George Nasioulas, PhD1

Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction

Dimitrios C. Ziogas 1,*,† , Eirini Papadopoulou 2,†, Helen Gogas 1 , Stratigoula Sakellariou 3, Evangellos Felekouras 4, Charalampos Theocharopoulos 1, Dimitra T. Stefanou 1, Maria Theochari 1, Ioannis Boukovinas 5, Dimitris Matthaios 6, Anna Koumarianou 7 , Eleni Zairi 8, Michalis Liontos 9 , Konstantinos Koutsoukos 9, Vasiliki Metaxa-Mariatou 2, George Kapetsis 2, Angeliki Meintani 2, Georgios N. Tsaousis 2 and George Nasioulas 2

Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing

Konstantinos Agiannitopoulos 1,*,Kevisa Potska 1,Anastasia Katseli 1,Christina Ntogka 1,Georgios N. Tsaousis 1ORCID,Georgia Pepe 1,Dimitra Bouzarelou 1,Nikolaos Tsoulos 1ORCID,Athanasios Papathanasiou 1ORCID,Dimitrios Ziogas 2ORCID,Vassileios Venizelos 3,Christos Markopoulos 4,Rodoniki Iosifidou 5,Sofia Karageorgopoulou 6,Stylianos Giassas 6,Ioannis Natsiopoulos 7,Konstantinos Papazisis 8,Maria Vasilaki-Antonatou 9,Amanta Psyrri 10,Anna Koumarianou 10ORCID,Dimitrios Matthaios 11,Eleni Zairi 12,Alexandru Blidaru 13,Eugeniu Banu 14,Dan Corneliu Jinga 15,Şahin Laçin 16,Mustafa Özdoğan 17,Eirini Papadopoulou 1 and George Nasioulas

RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis

AIKATERINI TSANTIKIDI1 , KONSTANTINOS PAPAZISIS2 , THEOFANIS FLOROS3 , MARIA GAZOULI4 , EIRINI PAPADOPOULOU1 , GEORGIOS TSAOUSIS1 , GEORGIOS NASIOULAS1 , ANDRA MESTER5 , KUBELAC PAUL MILAN5 , BOGDAN GOZMAN6 , VLAD AFRASANIE6 , DANA LUCIA STANCULEANU7 , OANA TRIFANESCU7 , FLORENTINA PESCARU8 , CLAUDIA MILITARU9 and CHRISTOS PAPADIMITRIOU1

Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing

KONSTANTINOS AGIANNITOPOULOS1, GEORGIA PEPE1, GEORGIOS N. TSAOUSIS1, KEVISA POTSKA1, DIMITRA BOUZARELOU1, ANASTASIA KATSELI 1, CHRISTINA NTOGKA1, ANGELIKI MEINTANI 1, NIKOLAOS TSOULOS1, STYLIANOS GIASSAS2, VASSILEIOS VENIZELOS3, CHRISTOS MARKOPOULOS4, RODONIKI IOSIFIDOU5, SOFIA KARAGEORGOPOULOU2, CHRISTOS CHRISTODOULOU3, IOANNIS NATSIOPOULOS6, KONSTANTINOS PAPAZISIS7, MARIA VASILAKI-ANTONATOU8, ELEFTHERIOS KABLETSAS9, AMANTA PSYRRI 10, DIMITRIOS ZIOGAS11, EFTHALIA LALLA4, ANNA KOUMARIANOU10, KORNILIA ANASTASAKOU3, CHRISTOS PAPADIMITRIOU12, VAHIT OZMEN13, SUALP TANSAN14, KERIM KABAN15, TAHSIN OZATLI 16, DAN TUDOR ENIU17, ANGELICA CHIOREAN18, ALEXANDRU BLIDARU19, MARRIT RINSMA20, EIRINI PAPADOPOULOU1 and GEORGE NASIOULAS1

Application of next generation sequencing in cardiology: current and future precision medicine implications

Eirini Papadopoulou1 *, Dimitra Bouzarelou1 , George Tsaousis1 , Athanasios Papathanasiou1 , Georgia Vogiatzi2 , Charalambos Vlachopoulos3 , Antigoni Miliou3 , Panagiota Papachristou4 , Efstathia Prappa5 , Georgios Servos6 , Konstantinos Ritsatos7 , Aristeidis Seretis7 , Alexandra Frogoudaki8 and George Nasioulas1

Genetic Predisposition to Male Breast Cancer: A Case Series

Angela Apessos, Konstantinos Agiannitopoulos, Georgia Pepe, Georgios N. Tsaousis, Panagiota Pitta, Chrysanthi Bili, Lina Florentin, Emmanouel Saloustros, Eleftherios Kampletsas, Dimitrios Tryfonopoulos, Nikolaos Tsoukalas, Evangelos Bournakis, Flora Zagouri, Athanassios Kotsakis, Anna Koumarianou, Ippokratis Korantzis, Ioannis Boukovinas, George Lypas, Georgios Fountzilas, Vasiliki Michalaki, Spyridon Xynogalos, Helena Linardou, Eirini Papadopoulou, George Nasioulas and Vassilis Georgoulias

A novel deletion of exon 4 in the Ectodysplasin A gene associated with X-linked hypohidrotic ectodermal dysplasia

Konstantinos Agiannitopoulos, Georgios N. Tsaousis , Kevisa Potska , Eirini Papadopoulou , Anna Douka, George Nasioulas , Iphigenia Gintoni , Christos Yapijakis

The evolution of comprehensive genetic analysis in neurology: Implications for precision medicine

Eirini Papadopoulou a,* , Georgia Pepe a , Spiridon Konitsiotis b , Maria Chondrogiorgi b , Nikolaos Grigoriadis c , Vasilios K. Kimiskidis d , Georgios Tsivgoulis e , Dimos D. Mitsikostasf , Elisabeth Chroni g , Eleni Domouzoglou h , Georgios Tsaousis a , Georgios Nasioulas a

CNV and RNA analysis reveal a germline pathogenic duplication of MSH2 exon 15 in a family with Lynch syndrome: A case report

Despina Apostolopoulou1 ; Mustafa Özdoğan2 ; Konstantinos Agiannitopoulos1 *; Georgia Pepe1 ; Kevisa Potska1 ; Georgios N Tsaousis1 ; Nikolaos Tsoulos1 ; Eleni Patsea3 ; Onder Kırca2 ; Muharrem Okan Çakır4 ; Eirini Papadopoulou1 ; George Nasioulas1

Importance of multigene panel test in patients with consanguineous marriage and family history of breast cancer

Vahit Ozmen, Ahmet Okay Caglayan, Kanay Yararbas, Cetin Ordu, Fatma Aktepe, Tolga Ozmen, Ahmet Serkan Ilgun, Gursel Soybir, Gul Alco, Georgios N Tsaousis, Eirini Papadopoulou, Konstantinos Agiannitopoulos, Georgia Pepe, Stavroula Kampouri, George Nasioulas, Efe Sezgin, Atilla Soran

Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients

Georgios N Tsaousis, Eirini Papadopoulou, Konstantinos Agiannitopoulos, Georgia Pepe, Nikolaos Tsoulos, Ioannis Boukovinas, Theofanis Floros, Rodoniki Iosifidou, Ourania Katopodi, Anna Koumarianou, Christos Markopoulos, Konstantinos Papazisis, Vasileios Venizelos, Achilleas Kapsimalis, Grigorios Xepapadakis, Amanda Psyrri, Eugeniu Banu, Dan Tudor Eniu, Alexandru Blidaru, Dana Lucia Stanculeanu, Andrei Ungureanu, Vahit Ozmen, Sualp Tansan, Mehmet Tekinel, Suayib Yalcin, George Nasioulas

Comprehensive tumor molecular profile analysis in clinical practice

Mustafa Özdoğan, Eirini Papadopoulou, corresponding author Nikolaos Tsoulos, Aikaterini Tsantikidi, Vasiliki-Metaxa Mariatou,Georgios Tsaousis, Evgenia Kapeni, Evgenia Bourkoula, Dimitrios Fotiou, Georgios Kapetsis, Ioannis Boukovinas, Nikolaos Touroutoglou, Athanasios Fassas, Achilleas Adamidis, Paraskevas Kosmidis, Dimitrios Trafalis, Eleni Galani,George Lypas, Bülent Orhan, Sualp Tansan, Tahsin Özatlı, Onder Kırca, Okan Çakır, and George Nasioulas

Clinical Utility of Functional RNA Analysis for the Reclassification of Splicing Gene Variants in Hereditary Cancer

Konstantinos Agiannitopoulos, Georgia Pepe, Eirini Papadopoulou, Georgios N. Tsaousis, Stavroula Kampouri, Sonia Maravelaki, Athanassios Fassas, Christos Christodoulou, Rodoniki Iosifidou, Sofia Karageorgopoulou, Christos Markopoulos, Ioannis Natsiopoulos, Konstantinos Papazisis, Maria Vasilaki-Antonatou, Vassileios Venizelos, Vahit Ozmen, Sualp Tansan, Kerim Kaban, Dan Tudor Eniu, Angelica Chiorean and George Nasioulas

Report of a germline double heterozygote in MSH2 and PALB2

Konstantinos Agiannitopoulos, Eirini Papadopoulou, Georgios N. Tsaousis, Georgia Pepe,Stavroula Kampouri, Eleni Patsea, George Lypas

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.

Eirini PapadopoulouID, Nikolaos Tsoulos, Katerina Tsantikidi, Vasiliki Metaxa- Mariatou,Pinelopi Eleftheria Stamou, Athina Kladi-Skandali, Evgenia Kapeni, Georgios Tsaousis

Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: a case report

Konstantinos Agiannitopoulos, Eirini Papadopoulou, Georgios N. Tsaousis, Georgia Pepe, Stavroula Kampouri, Mehmet Ali Kocdor and George Nasioulas

Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.

Tsaousis G, Papadopoulou E, Apessos A, Agiannitopoulos K, Pepe G, Kampouri S, Diamantopoulos N, Floros T, Iosifidou R, Katopodi O, Koumarianou A, Markopoulos C, Papazisis K, Venizelos V, Xanthakis I, Xepapadakis G, Banu E, Eniu DT, Negru S, Stanculeanu DL, Ungureanu A, Ozmen V, Tansan S, Tekinel M, Yalcin S and Nasioulas G, BMC Cancer 2019 19:535

Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center.

Apessos A, Agiannitopoulos K, Pepe G, Tsaousis GN, Papadopoulou E, Metaxa-Mariatou V, Tsirigoti A, Efstathiadou C, Markopoulos C, Xepapadakis G, Venizelos V, Tsiftsoglou A, Natsiopoulos I, Nasioulas G.
Cancer Genet. 2018 Jan;220:1-12.

Tumor molecular profiling of NSCLC patients using next generation sequencing.

Tsoulos N, Papadopoulou E, Metaxa-Mariatou V, Tsaousis G, Efstathiadou C, Tounta G, Scapeti A, Bourkoula E, Zarogoulidis P, Pentheroudakis G, Kakolyris S, Boukovinas I, Papakotoulas P, Athanasiadis E, Floros T, Koumarianou A, Barbounis V, Dinischiotu A, Nasioulas G.
Oncol Rep. 2017 Dec;38(6):3419-3429.

Molecular predictive markers in tumors of the gastrointestinal tract.

Papadopoulou E, Metaxa-Mariatou V, Tsaousis G, Tsoulos N, Tsirigoti A, Efstathiadou C, Apessos A, Agiannitopoulos K, Pepe G, Bourkoula E, Nasioulas G.
World J Gastrointest Oncol. 2016 Nov 15;8(11):772-785. Review.

Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients.

Papadopoulou E, Tsoulos N, Tsirigoti A, Apessos A, Agiannitopoulos K, Metaxa-Mariatou V, Zarogoulidis K, Zarogoulidis P, Kasarakis D, Kakolyris S, Dahabreh J, Vlastos F, Zoublios C, Rapti A, Papageorgiou NG, Veldekis D, Gaga M, Aravantinos G, Karavasilis V, Karagiannidis N, Nasioulas G.
Oncol Lett. 2015 Oct;10(4):2176-2184.

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study

Negru S, Papadopoulou E, Apessos A, Stanculeanu DL, Ciuleanu E, Volovat C, Croitoru A, Kakolyris S, Aravantinos G, Ziras N, Athanasiadis E, Touroutoglou N, Pavlidis N, Kalofonos HP, Nasioulas G.
BMJ Open. 2014 May 23;4(5):e004652.

Different genomic rearrangements account for 17% of BRCA1/2 mutations in Greece.

Angela Apessos, Eirini Papadopoulou, Vassiliki Metaxa-Mariatou, Konstantinos Agiannitopoulos et al.

Genekor

Posters

  1. 2025

    PDF

    P113_Li-Fraumeni_Genetic testing of Breast_ovarian cancer patients unmask familial pathogenic germline variants in TP53 gene_Clinical implications and family counselling

  2. 2025

    PDF

    P075_The Benefits of comprehensive NGS Panels using Liquid Biopsy in Breast Cancer

  3. 2025

    PDF

    P051_Exploring the clinical utility of Oncotype DX in ER+HER2-, N0 and N1 breast cancer patients Insights from a Romanian cohort

  4. 2025

    PDF

    P050_Genomic risk assessment with Oncotype DX in young women (age ≤ 40 years old) with early-stage ER+HER2-N0 breast cancer

  5. 2025

    PDF

    P049_The prognostic role of Ki-67 in relation to Oncotype DX Recurrence Score

  6. 2025

    PDF

    P044_Examining the Correlation and Concordance Between Ki-67 Expression and Oncotype DX Recurrence Score_Findings from a Multicenter Study in Turkey

  7. 2024

    PDF

    PR status cannot predict OncotypeDX Recurrence Score®: a study in a Greek cohort of N0M0/ER+/PR-/HER2- breast cancer patients tested with Oncotype DX

  8. 2024

    PDF

    The prognostic and predictive value of OncotypeDX® in ER+/HER2-/pT2N0, cM0 Breast Cancer Patients

  9. 2024

    PDF

    Low level constitutional mosaicism in breast cancer patients

  10. 2024

    PDF

    MAPPING OF GENE VARIANTS IN 7,587 SUBJECTS REFERRED FOR HEREDITARY CANCER

  11. 2022

    PDF

    Polygenic Risk Score in a cohort of 105 Breast Cancer patients previously tested with a multi gene panel for hereditary cancer

  12. 2022

    PDF

    Next Generation Sequencing (NGS) for the identification of PARP inhibitors’ predictive biomarkers.

  13. 2022

    PDF

    Cascade genetic testing utilized only in 31% of initial families with pathogenic variants in breast cancer genes

  14. 2022

    PDF

    Copy Number Variations (CNVs) and Hereditary Breast Cancer

  15. 2019

    PDF

    Multigene panel testing results for hereditary breast cancer - ESMO 2019

  16. 2018

    PDF

    Tumor Mutational Burden TMB - poster at ECCB 2018

  17. 2017

    PDF

    Analysis of hereditary cancer syndromes by use of a panel of genes: More answers than questions

  18. 2016

    PDF

    BRCA Early Access program - poster at ECP

  19. 2014

    PDF

    CTRC-AACR San Antonio Breast Cancer Symposium 2014

  20. 2013

    PDF

    St. Gallen 2013 OncotypeDX

  21. 2013

    PDF

    St. Gallen 2013 BRCA

  22. 2012

    PDF

    EANO 2012

  23. 2012

    PDF

    ASCO 2012 EGFR

  24. 2012

    PDF

    ASCO 2012 ALK

  25. 2011

    PDF

    St. Gallen 2011

  26. 2011

    PDF

    ESMO 2011 ALK

  27. 2011

    PDF

    ESMO 2011 EGFR